Clinical Trial Update: Phase 3 Study of KHK7580 [Phase 3]

View source ↗

Summary

A Phase 3 study of Kyowa Kirin's KHK7580 for secondary hyperparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• KHK7580

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 3 | Status: COMPLETED